Stock data
TG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. (TGTX) reported revenue of US$616.29M and net income of US$447.18M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$616.29M | — | US$123.32M | US$447.18M | — |
| 2024 | US$329.00M | — | US$41.93M | US$23.38M | — |
| 2023 | US$233.66M | — | US$20.63M | US$12.67M | — |
| 2022 | US$2.79M | — | -US$218.32M | -US$223.81M | — |
| 2021 | US$6.69M | — | -US$344.77M | -US$348.10M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$240.34M | US$7.78M | — |
| 2026-03-31 | US$204.92M | US$19.78M | — |
| 2025-12-31 | US$192.57M | US$23.04M | — |
| 2025-09-30 | US$161.71M | US$390.89M | — |
| 2025-06-30 | US$141.15M | US$28.19M | — |
| 2025-03-31 | US$120.86M | US$5.06M | — |
| 2024-12-31 | US$108.19M | US$23.33M | — |
| 2024-09-30 | US$83.88M | US$3.88M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.